The Apex Times
Above the Noise
Business Wire
BusinessGoldman and JPMorgan shares climb before major bank earnings; investors show signs of rotating toward financeThe Apex TimesBusinessUnitedHealth’s Earnings Top Wall Street Estimates as Medical-Cost Pressure Shows Signs of EasingThe Apex TimesBusinessUnitedHealth raises full-year 2026 guidance after reporting third-quarter resultsThe Apex TimesBusinessHolm Security rolls out Microsoft 365 security assessment as it expands vulnerability management platformThe Apex TimesBusinessUnitedHealth reports third-quarter profit, shares focus turns to what drove results and guidanceThe Apex TimesBusinessBroadcom CEO Hock Tan tells investors they do not understand what they own, invoking a Warren Buffett lessonThe Apex TimesBusinessNetflix drops the official trailer for Mariano Barroso’s “The Child,” starring Belén Cuesta and Karra ElejaldeThe Apex TimesBusinessMark Zuckerberg says Meta’s new “Muse Wonder” AI marks a major leap and aims to become a personal toolThe Apex TimesBusinessTesla’s Cybertruck deliveries may be getting worse to read into, after reporting change exposes vehicle salesThe Apex TimesBusinessEli Lilly forecasts up to $87 billion in 2026 revenue as investors weigh how much growth is already priced inThe Apex TimesBusinessVisa Receives China Approval for Domestic Card Clearing PushThe Apex TimesBusinessA 63-Year-Old Takes a Part-Time UPS Loading Job, With Pay Stated at About $1,800 a MonthThe Apex TimesBusinessGoldman and JPMorgan shares climb before major bank earnings; investors show signs of rotating toward financeThe Apex TimesBusinessUnitedHealth’s Earnings Top Wall Street Estimates as Medical-Cost Pressure Shows Signs of EasingThe Apex TimesBusinessUnitedHealth raises full-year 2026 guidance after reporting third-quarter resultsThe Apex TimesBusinessHolm Security rolls out Microsoft 365 security assessment as it expands vulnerability management platformThe Apex TimesBusinessUnitedHealth reports third-quarter profit, shares focus turns to what drove results and guidanceThe Apex TimesBusinessBroadcom CEO Hock Tan tells investors they do not understand what they own, invoking a Warren Buffett lessonThe Apex TimesBusinessNetflix drops the official trailer for Mariano Barroso’s “The Child,” starring Belén Cuesta and Karra ElejaldeThe Apex TimesBusinessMark Zuckerberg says Meta’s new “Muse Wonder” AI marks a major leap and aims to become a personal toolThe Apex TimesBusinessTesla’s Cybertruck deliveries may be getting worse to read into, after reporting change exposes vehicle salesThe Apex TimesBusinessEli Lilly forecasts up to $87 billion in 2026 revenue as investors weigh how much growth is already priced inThe Apex TimesBusinessVisa Receives China Approval for Domestic Card Clearing PushThe Apex TimesBusinessA 63-Year-Old Takes a Part-Time UPS Loading Job, With Pay Stated at About $1,800 a MonthThe Apex TimesBusinessGoldman and JPMorgan shares climb before major bank earnings; investors show signs of rotating toward financeThe Apex TimesBusinessUnitedHealth’s Earnings Top Wall Street Estimates as Medical-Cost Pressure Shows Signs of EasingThe Apex TimesBusinessUnitedHealth raises full-year 2026 guidance after reporting third-quarter resultsThe Apex TimesBusinessHolm Security rolls out Microsoft 365 security assessment as it expands vulnerability management platformThe Apex TimesBusinessUnitedHealth reports third-quarter profit, shares focus turns to what drove results and guidanceThe Apex TimesBusinessBroadcom CEO Hock Tan tells investors they do not understand what they own, invoking a Warren Buffett lessonThe Apex TimesBusinessNetflix drops the official trailer for Mariano Barroso’s “The Child,” starring Belén Cuesta and Karra ElejaldeThe Apex TimesBusinessMark Zuckerberg says Meta’s new “Muse Wonder” AI marks a major leap and aims to become a personal toolThe Apex TimesBusinessTesla’s Cybertruck deliveries may be getting worse to read into, after reporting change exposes vehicle salesThe Apex TimesBusinessEli Lilly forecasts up to $87 billion in 2026 revenue as investors weigh how much growth is already priced inThe Apex TimesBusinessVisa Receives China Approval for Domestic Card Clearing PushThe Apex TimesBusinessA 63-Year-Old Takes a Part-Time UPS Loading Job, With Pay Stated at About $1,800 a MonthThe Apex TimesBusinessGoldman and JPMorgan shares climb before major bank earnings; investors show signs of rotating toward financeThe Apex TimesBusinessUnitedHealth’s Earnings Top Wall Street Estimates as Medical-Cost Pressure Shows Signs of EasingThe Apex TimesBusinessUnitedHealth raises full-year 2026 guidance after reporting third-quarter resultsThe Apex TimesBusinessHolm Security rolls out Microsoft 365 security assessment as it expands vulnerability management platformThe Apex TimesBusinessUnitedHealth reports third-quarter profit, shares focus turns to what drove results and guidanceThe Apex TimesBusinessBroadcom CEO Hock Tan tells investors they do not understand what they own, invoking a Warren Buffett lessonThe Apex TimesBusinessNetflix drops the official trailer for Mariano Barroso’s “The Child,” starring Belén Cuesta and Karra ElejaldeThe Apex TimesBusinessMark Zuckerberg says Meta’s new “Muse Wonder” AI marks a major leap and aims to become a personal toolThe Apex TimesBusinessTesla’s Cybertruck deliveries may be getting worse to read into, after reporting change exposes vehicle salesThe Apex TimesBusinessEli Lilly forecasts up to $87 billion in 2026 revenue as investors weigh how much growth is already priced inThe Apex TimesBusinessVisa Receives China Approval for Domestic Card Clearing PushThe Apex TimesBusinessA 63-Year-Old Takes a Part-Time UPS Loading Job, With Pay Stated at About $1,800 a MonthThe Apex Times
Back to front
Johnson & Johnson (JNJ) valuation debate reopens after TREMFYA data highlights drug momentum
The Apex Times

THE APEX TIMES

Business/The Apex Times/Oct 13, 5:42 AM EDT

Johnson & Johnson (JNJ) valuation debate reopens after TREMFYA data highlights drug momentum

A market analysis tied to recent TREMFYA clinical results argues J&J shares could be trading below a perceived intrinsic value, while investors weigh how durable the cash-generating outlook will be.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Johnson & Johnson is back in the spotlight for valuation watchers after a new market note suggested the company’s stock may be trading about 28% below an estimate of intrinsic value. The argument, attributed to analysis in the Yahoo Finance piece, centers on whether the company’s pipeline and cash flow drivers are strong enough to justify the way the market is currently pricing the business.

The catalyst cited in the report is additional data connected to TREMFYA, Johnson & Johnson’s psoriasis and psoriatic arthritis medicine (TREMFYA is the brand name for guselkumab). The analysis characterizes the data as “impressive” and links it to the prospect that the drug’s performance and future contribution to sales could be underestimated by the stock market.

Beyond the clinical headline, the core issue is not the existence of growth, but the magnitude and staying power of it. The Yahoo Finance article frames the discussion around whether the business can convert those medical and development updates into enough free cash flow, which is the cash left after operating costs and capital spending, to support the expectations embedded in today’s share price.

The note also reflects a broader tension that has followed many large pharma companies into 2026: investors can acknowledge product progress, yet still discount long-term cash generation if they believe patents, competitive pressure, or pipeline risk will limit durability. In that context, the report’s “undervalued” claim is effectively a bet that TREMFYA’s outlook and related opportunities are better than what current valuation multiples imply.

For Johnson & Johnson, TREMFYA’s role matters because therapies in immunology categories have become a key growth pillar for large drugmakers, and J&J has been working to sustain returns as parts of the portfolio mature. While the Yahoo Finance post spotlights TREMFYA data as the immediate driver, it implicitly points to the company’s wider pipeline question: can new evidence extend product lifecycles and reduce uncertainty in projected earnings power?

What the market note does not provide in the material available here is the specific endpoints, magnitude of effect, patient populations, or duration of follow-up referenced as “impressive.” It also does not disclose the precise valuation method behind the 28% figure in the information provided, nor does it break out key assumptions such as expected market share, pricing, or timing of uptake.

Investors who are weighing similar valuation arguments may want to focus on what investors will see next from J&J, including any additional regulatory or label-expansion steps connected to TREMFYA, plus updates that clarify how much of the company’s future revenue growth is already “priced in.” The stock’s reaction could depend less on the headline of new clinical data and more on how that data shifts forward expectations for sustained cash flow.

Why It Matters

  • If investors accept that TREMFYA’s outlook is stronger than expected, it could change expectations for Johnson & Johnson’s longer-term earnings and cash generation.
  • Valuation disagreements like the 28% estimate often announcement that market expectations may be shifting, even when overall fundamentals have not changed.
  • The market’s focus on free cash flow highlights how important cash conversion and spending discipline are for large-cap healthcare valuations.

Sources

Key Facts

  • A Yahoo Finance market note says Johnson & Johnson (JNJ) shares may be trading roughly 28% below an estimated intrinsic value.
  • The analysis links the valuation debate to updated TREMFYA data, describing it as “impressive.”
  • TREMFYA is guselkumab, a therapy used in inflammatory conditions such as psoriasis and psoriatic arthritis.
  • The reported thesis centers on whether Johnson & Johnson can generate enough cash flow to support the stock’s current pricing.
  • Specific clinical details, assumptions behind the valuation estimate, and the calculation method are not provided in the information available here.

Healthcare Related